How has Imran Alibhai's remuneration changed compared to Tvardi Therapeutics's earnings?
Date
Total Compensation
Salary
Company Earnings
Mar 31 2026
n/a
n/a
-US$15m
Dec 31 2025
US$3m
US$620k
-US$18m
Sep 30 2025
n/a
n/a
-US$24m
Jun 30 2025
n/a
n/a
-US$24m
Mar 31 2025
n/a
n/a
-US$35m
Dec 31 2024
US$857k
US$551k
-US$29m
Sep 30 2024
n/a
n/a
-US$21m
Dec 31 2023
US$831k
US$535k
-US$17m
Compensation vs Market: Imran's total compensation ($USD3.12M) is above average for companies of similar size in the US market ($USD658.00K).
Compensation vs Earnings: Imran's compensation has increased whilst the company is unprofitable.
CEO
Imran Alibhai (50 yo)
no data
Tenure
US$3,116,090
Compensation
Dr. Imran Alibhai, Ph D, serves as Chief Executive Officer and Director of Tvardi Therapeutics, Inc. He served as Senior Vice President of Business Development at DNAtrix, Inc until December 2018 and also...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Imran Alibhai
CEO & Director
no data
US$3.12m
4.7% $ 1.5m
Dan Conn
CFO & Corporate Secretary
3.8yrs
US$1.14m
1.14% $ 355.2k
John Kauh
Chief Medical Officer
3.4yrs
US$1.16m
0.83% $ 256.6k
David Tweardy
Co-Founder & Scientific Advisory Board Member
9.5yrs
no data
6.91% $ 2.1m
Ronald DePinho
Co-Founder & Chairman of Scientific Advisory Board
9.5yrs
no data
4.54% $ 1.4m
Michael Lewis
Co-Founder & Scientific Advisory Board Member
no data
no data
no data
Jeffrey Larson
Senior Vice President of R&D
5.5yrs
no data
no data
Stephen O'Brien
VP of Finance & Corporate Controller
no data
no data
no data
Yixin Chen
Vice President of CMC
no data
no data
no data
5.5yrs
Average Tenure
61yo
Average Age
Experienced Management: TVRD's management team is seasoned and experienced (5.5 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Imran Alibhai
CEO & Director
no data
US$3.12m
4.7% $ 1.5m
David Tweardy
Co-Founder & Scientific Advisory Board Member
no data
no data
6.91% $ 2.1m
Ronald DePinho
Co-Founder & Chairman of Scientific Advisory Board
no data
no data
4.54% $ 1.4m
Michael Lewis
Co-Founder & Scientific Advisory Board Member
no data
no data
no data
Michael Wyzga
Independent Director
5.3yrs
US$170.56k
0.24% $ 74.3k
Keith Flaherty
Scientific Advisory Board Member
no data
no data
no data
Cynthia Smith
Independent Director
1.5yrs
US$155.17k
0.043% $ 13.2k
Sujal Shah
Independent Chairman
5.5yrs
US$184.16k
0.24% $ 74.3k
Susan Shiff
Independent Director
1.5yrs
US$264.99k
0.060% $ 18.6k
Wallace Hall
Independent Director
no data
US$155.53k
0.48% $ 148.0k
3.4yrs
Average Tenure
60yo
Average Age
Experienced Board: TVRD's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/14 04:30
End of Day Share Price
2026/07/14 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tvardi Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.